Non-arteritic anterior ischemic optic neuropathy (NA-AION) represents one of the most
important causes of blindness or severely impaired vision in middle-aged and elderly …

Importance Anecdotal experience raised the possibility that semaglutide, a glucagon-like
peptide 1 receptor agonist (GLP-1 RA) with rapidly increasing use, is associated with …

Glaucoma is a progressive neurodegenerative disease that frequently results in irreversible
blindness. Glaucoma causes death of retinal ganglion cells (RGCs) and their axons in the …

Objective: We conducted a meta-analysis to explore all the potential risk factors for non-
arteritic anterior ischemic optic neuropathy (NAION) based on the published literature …

Purpose We describe the baseline ophthalmic and cardiovascular risk factors across
countries, race, and sex for the Quark207 treatment trial for acute nonarteritic anterior …

Purpose To investigate whether semaglutide increases the risk of nonarteritic anterior
ischemic optic neuropathy (NAION) in the general population. Design This retrospective …

PURPOSE OF REVIEW Vision is often threatened or lost by acute ischemic damage to the
optic nerves. Such pathology most often affects the anterior portion of the nerve and is …

Purpose Non-arteritic anterior ischemic optic neuropathy (NAION) is the most common
cause of non-glaucomatous optic neuropathy in older adults. Optical coherence …

Background The association of obstructive sleep apnea (OSA) with development of eye
diseases is unclear. This current systematic review and meta-analysis attempts to …

Objective To review treatment modalities that have been studied in acute non arteritic
anterior ischemic optic neuropathy (NAION). Methods We performed a comprehensive …